Albireo Pharma Inc. is hoping to initiate a Phase III study for its lead candidate, the selective ileal bile acid transporter (IBAT) inhibitor A4250, in the rare genetic disease progressive familial intrahepatic cholestasis (PFIC) by the end of the year.
At the American Association for the Study of Liver Diseases meeting Oct. 20-24, the Boston-based firm talked about its plans...







